Aspire Biopharma
ASBP
12 hedge funds and large institutions have $372K invested in Aspire Biopharma in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 18 closing their positions.
0.25% more ownership
Funds ownership: 0% → 0.25% (+0.25%)
57% less funds holding
Funds holding: 28 → 12 (-16)
59% less capital invested
Capital invested by funds: $900K → $372K (-$528K)
72% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 18
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$228K |
| 2 |
Morgan Stanley
New York
|
+$137K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$66K |
| 4 |
CA
Crossingbridge Advisors
Pleasantville,
New York
|
+$42.2K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$8.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$90.8K |
| 2 |
OAS
Optivise Advisory Services
Franklin,
Tennessee
|
-$47.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$35K |
| 4 |
PA
Procyon Advisors
Shelton,
Connecticut
|
-$30.7K |
| 5 |
RA
Resolute Advisors
San Francisco,
California
|
-$20.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PSAMP
26
P. Schoenfeld Asset Management (PSAM)
New York
| – | -$7.72K | -49 | Closed |
|
|
SRL
27
Scientech Research LLC
Jersey City,
New Jersey
| – | -$6.81K | -43 | Closed |
|
|
PC
28
Periscope Capital
Toronto,
Ontario, Canada
| – | -$6.59K | -42 | Closed |
|
|
PTP
29
Platform Technology Partners
New York
| – | -$4.96K | -31 | Closed |
|
30
Point72 Asset Management
Stamford,
Connecticut
| – | -$1.88K | -12 | Closed |
|
|
SG
31
StoneX Group
New York
| – | -$1.94K | -12 | Closed |
|
|
ACM
32
Allred Capital Management
Dallas,
Texas
| – | -$1.48K | -9 | Closed |
|
33
Fisher Asset Management
Camas,
Washington
| – | -$1.32K | -8 | Closed |
|
34
Bank of America
Charlotte,
North Carolina
| – | -$37 | – | – |
|
ASBP Hedge Fund Activity: Q1 2026 in Review
12 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q1 2026, worth a combined $372K — down 59% from $900K a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ASBP and 5 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $228K. The largest seller was Jane Street, exiting entirely with an estimated $90.8K sold.
- 12 institutional investors held Aspire Biopharma (ASBP) as of Q1 2026, down from 28 in Q4 2025.
- Funds reported $372K of Aspire Biopharma stock for Q1 2026, down 59% quarter-over-quarter.
- 5 funds opened new Aspire Biopharma positions in Q1 2026 and 18 closed out, a net change of -13 holders.
- The largest Aspire Biopharma buyer in Q1 2026 was UBS Group, an estimated $228K added.
- The largest Aspire Biopharma seller in Q1 2026 was Jane Street, an estimated $90.8K sold.
Based on aggregated 13F filings for Q1 2026.